ArticleNature communications2021
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Validation of a novel prognostic staging system for breast cancer incorporating age at diagnosis.Breast cancer research and treatment · 2026Article
- Breast Cancer Liver Metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.Research square · 2026Article
- Pregnancy-induced tissue-resident memory-like T cells contribute to tumor control in breast cancer.Nature immunology · 2026Article
- Decoding the Collagenome in Breast Cancer: Mechanotransduction, Microenvironment, and Translational Opportunities.International journal of molecular sciences · 2026Review
- Postpartum breast cancer as a distinct oncologic entity: linking physiological tissue remodelling to tumor biology and clinical translation.Breast cancer research : BCR · 2026Review
- SOX9 and SEMA7A regulate cell plasticity in the postpartum mammary gland with implications for breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Postpartum breast cancer: evidence for a distinct phenotype.Journal of the National Cancer Institute · 2026Article
- S-nitrosylated COX-2 is a microenvironment-regulated breast cancer cell biomarker of mesenchymal phenotypes.Experimental cell research · 2026Article
- Induction of senescence during postpartum mammary gland involution supports tissue remodeling and promotes postpartum tumorigenesis.Nature aging · 2026Article
- Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort.Cancers · 2025Article
- Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression.Breast cancer research : BCR · 2025Article
- Differential ER stress responses during lactation and postpartum outcomes in mice depending on their mitochondrial genotype.Nature communications · 2025Article
- Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer.Cell reports · 2025Article
- Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.NPJ breast cancer · 2025Review
- Article
- Pregnancy and breast cancer in young women: current updates and future directions.Therapeutic advances in medical oncology · 2025Review
- Maternal ancestry reveals cyclical aging of the mammary gland.Research square · 2024Article
- Towards targeting the breast cancer immune microenvironment.Nature reviews. Cancer · 2024Review
- Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Young women's breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5-10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.